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HBV and IICV genome in peripheral blood mononuclear cells in
patients undergoing chronic hemodialysis. Patients undergoing chronic
hemodialysis are at risk for infection with hepatitis B virus (HBV) and
hepatitis C virus (HCV). As peripheral blood mononuclear cells
(PMNC) are known to be susceptible to infection of both HBV and
HCV, assessment of viral genomes in those cells could uncover occult
infections not detected by serologic methods or virus determination in
serum. We investigated all 67 patients undergoing chronic hemodialysis
at a single dialysis unit by PCR for the presence of HBV or HCV
genomes in serum as well as in PMNC. None of the 67 patients was
HB5Ag positive or showed HBV-DNA in serum, but in 5 patients
HBV-DNA in PMNC was detected as the only marker of HBV-
infection; those patients were also anti-HBc negative. In 9 patients
HCV-RNA was positive in serum; in 5 of those patients it was also
found in PMNC. Three of these infected patients were negative for
anti-HCV. One other patient had no anti-HCV or HCV-RNA in
serum, but was positive for HCV-RNA in PMNC. Thus, in 6 patients
(8.9%) undergoing chronic hemodialysis we found evidence of infec-
tion with HBV or HCV by detecting viral genomes in PMNC without
the presence of viremia, antigenemia or specific viral antibodies in
serum. The detection of viral genomes in PMNC could be useful in the
positive identification of additional potentially infectious patients.
Patients undergoing chronic intermittent hemodialysis carry a
variable risk for acquiring infections with hepatitis B (HBV) and
hepatitis C (HCV) virus [1]. With HBV infection still present but less
prevalent in that group (5.6%) [11, the growing impact of HCV
infection has been documented in several surveys showing seropreva-
lence rates from 8% to 55% [2, 3]. Several variables such as duration
of hemodialysis [41, past history of blood transfusion or number of
blood units transfused [51 were associated with infection.
The currently available tools for detecting infection with
HBV or HCV by testing for virus-specific antibodies, circulat-
ing viral antigens, or blood-borne viral genomes (HBV-DNA or
HCV-RNA) are powerful methods, but have inherent limita-
tions either due to the given sensitivity of the tests, low viremia,
or due to host factors such as a compromised immune system
leading to impaired antibody response. Besides being detect-
able in serum, both HBV [6] and, more recently, HCV [7, 8]
have been shown to infect peripheral blood mononuclear cells
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(PMNC), as well. Infected PMNC have been implicated as a
potentially infectious viral reservoir [9] where HBV and HCV
might undergo extrahepatic replication. Even in the absence of
HBV-DNA [6] or HCV-RNA in serum [101 hepatitis virus
genomes can be present in PMNC. Thus, testing for HBV or
HCV viral genomes in PMNC might enhance the chances of
detecting viral infection.
We investigated the prevalence of HBV and HCV infection in
patients undergoing chronic hemodialysis by testing for viral
antigens (HB5Ag, HBeAg), viral antibodies (anti-HB5, anti-HBc,
anti-HBe, anti-HCV), as well as the presence of viral genomes
(HBV-DNA and HCV-RNA) in both serum and PMNC. We
report that a considerable percentage of patients has evidence of
infection with HBV or HCV in PMNC in the absence of viremia,
antigenemia or specific viral antibodies.
Methods
Patients
All 67 patients (35 male, 32 female, mean 55 16 years, range
22 to 83 years) undergoing chronic hemodialysis at dialysis unit I
of the Universitatsklinik fur Innere Medizin III, University of
Vienna, were investigated. Renal disorders resulting in end-stage
kidney disease were chronic glomerular nephritis (19 patients),
diabetic nephropathy (8 patients), analgesic nephropathy (6 pa-
tients), interstitial nephritis (9 patients), and miscellaneous causes
(8 patients). In 17 patients the etiology of end-stage renal disease
was not established. Mean duration of chronic hemodialysis was
44 34 months, the mean number of transfused blood units was
3.9 3.7 (range: 0 to 25). In regular intervals (every 3 months)
infection with hepatitis virus B or C was checked by serologic
methods. Serological determination of HBV markers (HBsAg,
anti-HBs, anti-HBc, HBeAg, anti-HBe; Abbott) and of HCV
markers (3 generation; Abbott Laboratories) were performed by
ELISA method using commercially available kits. New patients
entering the chronic hemodialysis program were routinely as-
sessed for the presence of anti-HBs; 52 patients negative for anti-
HBs were vaccinated with double dose of a recombinant hepatitis
B vaccine (Engerix B; Smith, Kline, Beecham) given i.m. three
times in monthly intervals. This vaccination regime resulted in the
seroconversion to anti-HBs in 32 patients (62%), whereas 20
patients (38%) were non-responders to vaccination. Laboratory
data of the patients included in this study are given in Table 1.
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All
Patients Patients
witha without5
Evidence for presence
patients of viral genomes P°
Number of patients 67 15 52
AST U/liter 9 9 13 12 8 7
ALT U/liter 9 8 14 9 8 7
YGT U/liter 48 98 99 150 33 74
AP U/liter 152 113 227 148 130 91
CHE kU/liter 3.9 1.1 3.2 1.2 4.0 1.1
bilirubin mg/dl 0.4 0.2 0.4 0.2 0.4 0.1
albumin g/liter 42 3.8 41 5.3 42 3.4
° positive for HBV-DNA or HCV-RNA in serum and/or PMNC
' negative for HBV-DNA or HCV-RNA in serum and PMNC
° P values of t-test between patients with and without evidence for
presence of viral genomes
Controls
Serum and PMNC of 16 HBsAg+ patients with chronic hepa-
titis B, of 15 patients with chronic hepatitis C, and of 21 healthy
control persons were also analyzed.
Processing of blood samples
Serum samples and heparinized peripheral venous blood was
collected at the same time from each patient using the vacutainer
system (Becton Dickinson). All sample handling was performed
under sterile conditions in a laminar air flow system in a dedicated
room separated from the area where PCR reactions were set up.
The recommended precautions to avoid contamination by PCR
product carryover and false-positive results were followed [11].
Peripheral blood mononuclear cells (PMNC) were separated by
buoyant density gradient centrifugation using Ficoll-Hypaque
(Pharmacia). The mononuclear cell fraction was aspirated and
washed six times with 30 ml of sterile 0.9% saline. This extensive
washing step has been shown in our laboratory to remove
serum-associated viral contamination from the PMNC fraction;
PCR from an aliquot of the last washing fluid was performed in
each patient and gave consistently negative results. Purified and
washed PMNC were counted, 2 to 5 x 106 PMNC were lysed in
500 .d 4 M guanidium isothiocyanate/1% 2-mercaptoethanol, and
stored at —70°C together with serum samples and art aliquot of
the last washing fluid.
Preparation of DNA samples
(a) From serum samples and last washing fluid of PMNC. One
hundred microliters of serum or washing fluid were incubated
overnight at 37°C with 100 1.d double-destilled H20 and 200 j.rl 2
X lysis buffer [0.1 M Na2EDTA, 0.1 M Hepes, 0.4 M NaCl, 4%
SDS; pH 7.2, proteinase K (2 mg/mi), yeast tRNA (50 rg/ml)].
The solution was phenol/chloroform extracted and DNA was
precipitated with isopropanol, dried and resuspended in 100 .d
H20.
(b) From PMNC. Two to 5 x 106 PMNC were lysed with 500 .rl
of 4 M guanidium isothiocyanat containing 1% mercaptoethanol.
The lysed cells were dialyzed in separate containers overnight in
1000 ml of TE buffer (10 mivi Tris pH 8.0, 1 mM EDTA) at 4°C and
incubated for one hour at 55°C with 10 pA of 10% SDS and 50 pA
of proteinase K (100mg/mi). The solution was extracted two times
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with phenol/chloroform, total DNA was precipitated with isopro-
panol, and resuspended in 100 pA H20. Total DNA content was
quantitated spectrophotometrically at 260 nm.
Oligonucleotide primers for HBV-PCR
A set of nested oligonucleotide primers specific for HBV was
used according to Kaneko, Feinstone and Miller [121. As outer
primers the oiigonucleotides 1763, 5 '-GCT-TTG-GGG-CAT-
GGA-CAT-TGA-CCC-GTA-TAA-3', and 2032R, 5 '-CTG-ACT-
ACT-AAT-TCC-CTG-GAT-GCT-GGG-TCT-3', and as inner
primers the oligonucleotides 1778E, 5 '-GAC-GAA-TTC-CAT-
TGA-CCC-GTA-TAA-AGA-ATT-3', and 2017RB, S '-ATG-
GGA-TCC-CFG-GAT-GCT-GGG-TO-TCC-AAA-3', were used.
The specificity of the amplified PCR product was assessed by
hybridization with the internal oligonucleotide HBVOLI1, 5'-
GT-ACT-CTC-GTT-TTI-GCC-TTC-TGA-CTF-CTT-3'.
PCR amplification of HBV-DNA
(a) From serum and washing fluid. DNA extracted from 1 p.l of
serum or the last washing fluid from PMNC was amplified in a 100
Ll reaction volume containing 1 U of Taq polymerase (Perkin
Elmer Cetus), 11 nmol dNTP, 10 pmol of each of the primers 1763
and 2032R in PCR buffer (10 mrvi Tris pH 8.3, 50 mM KC1, 1.5 mM
MgC12). The polymerase chain reaction was performed in a
thermocycler 9600 (Perkin Elmer Cetus) in 200 1.d MicroAmpRe-
action tubes (Perkin Elmer Cetus) and optimized according to the
following protocol: 5 minutes 95°C, 30 cycles of 15 seconds at
94°C, 15 seconds at 55°C, 30 seconds at 72°C, followed by 7
minutes 72°C. After completion of the first PCR 1 pJ of the
reaction volume was transferred to a second PCR tube containing
primers 1778E and 2017RB and run for 30 cycles as described
above. We were routinely able to detect 1 ag of cloned HBV-DNA
corresponding to 1 to 3 HBV particles per jil serum.
(b) From PMNC. One microgram of total DNA isolated from
PMNC was amplified in a nested PCR reaction using the same
PCR primers, PCR buffer and dNTP concentration as described
above, but concentrations of primers (100 pmol) and of Taq
polymerase (2.5 U) were optimized for the higher total DNA
content. Cycling conditions consisted of 5 minutes at 95°C, and 30
cycles of 1 minute at 94°C, 1 minute at 55°C, 1 minute at 72°C,
followed by an extension step for 7 minutes at 72°C. Sensitivity
was similar as compared to PCR from serum: 1 .rg of total cellular
DNA (roughly corresponding to 1 X i0 PMNC) spiked with 1 ag
of cloned HBV-DNA gave a positive result.
Preparation of RNA samples
(a) From serum and the last washing fluid of PMNC. 50 pA of
serum or last washing fluid was added to 200 pA of phosphate-
buffered saline and precipitated with 250 pA 16% polyethylene
glycol by incubation at 4°C overnight [13]. After precipitation the
tubes were spun down in a microfuge for 20 minutes at 4°C and
the supernatant was discarded. The pellet was totally dissolved in
500 1d denaturing solution (4.4 M guanidium thiocyanate, 25 mM
sodium citrate pH 7.0, 0.5% sarcosyl, 1% 2-mercaptoethanol).
After extraction with phenol/chloroform/isoamylalcohol 50 pA of
tRNA (1 mg/mi) was added and nucleic acids were precipitated
with absolute ethanol at —20°C overnight. After a further spun in
the microfuge for 20 minutes at 4°C the pellet was washed with
70% ethanol and centrifuged. Ethanol was drawn off and the
tubes were placed in a biological safety cabinet until the pellet was
Table 1. Liver function tests of patients (N = 67) undergoing chronic
hemodialysis
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dry. Thereafter the pellet was resuspended in 100 pd of double-
destilled water containing 40 U/pd RNAsin (Promega).
(b) From PMNC. Two to 5 X 106 PMNC were lysed with 1 ml
lysis buffer [10mM EDTA (pH 8.0), 0.5% SDSJ and 1 ml of 0.1 mM
sodium acetate (pH 5.2) and 10 mrvi EDTA (pH 8.0). This solution
was extracted twice with phenol/chloroform. Nucleic acids were
precipitated twice with ice cold I M Tris-HC1 (pH 8.0), 5 M NaCI,
and ethanol. The pellet was redissolved in 200 p1 H20 containing
7 U RNAsin and stored at —70°C.
Oligonucleotide primers for HCV-PCR
A set of nested oligonucleotide primers specific for the 5'-
untranslated region of HCV was used according to Hsu et al [14].
As outer primers the oligonucleotides Fl, 5'-GGC-GAC-ACT-
CA-CCA-TAG-ATC-3', and Ri, 5'-GGT-GCA-CGG-TCT-
ACG-AGA-CCT-3', and as inner primers the oligonucleotides
F3, 5 '-CGT-TGA-GGA-ACT-ACT-GTC-TFC-3', and R3, 5'-
CCC-TAT-CAG-GCA-GTA-CCA-CAA-3', were used.
PCR amplification of HCV-RNA
(a) From serum and washing fluid. PCR was performed in a
volume of 100 p.! containing RNA extracted from I p.! serum, 1 U
Taq polymerase, 1 U reverse transcriptase (Promega), 16 U
RNAsin, 40 pmol of each of the outer primers Fl and RI, 4 nmol
dNTP in PCR buffer. The cycling protocol, optimized for the
thermocycler 9600 (Perkin-Elmer) and the 200 pJ MicroAmpRe-
action tubes, was as follows: reverse transcription 30 minutes at
42°C, 5 minutes at 95°C; 25 cycles of 15 seconds at 95°C, 30
seconds at 55°C, 30 seconds at 72°C; extension step of 7 minutes
at 72°C. After completion of the first PCR 1 p.l of the reaction
volume was transferred to a second PCR tube containing primers
F3 and R3, 1 U Taq polymerase, 4 nmol dNTP in PCR buffer. The
cycling protocol was 4 minutes at 95°C; 25 cycles of 15 seconds at
95°C, 30 seconds at 55°C, 30 seconds at 72°C; and an extension
step of 7 minutes at 72°C. We were able to detect RNA corre-
sponding to 8 to 10 HCV particles/pd serum.
(b) From PMNC. Cycling conditions, primer concentrations (50
pmol), and concentration of Taq polymerase (2.5 U) were opti-
mized for the high content of nucleic acids. The cycling protocol
was identical to that used for serum except denaturing, annealing,
and extension times were prolonged to 1 minute each. We were
able to detect the lowest positive dilution of a HCV-RNA positive
standard serum when added to 1 X iO uninfected PMNC,
indicating that sensitivity of HCV-PCR from PMNC was in the
same range as from serum.
Analysis of amplified DNA
The amplified DNA product was analyzed on a 2% agarose
(Pharmacia) gel under UV-light after staining with ethidium
bromide. The expected amplicon of HBV-PCR was 256 bp, that of
HCV-PCR 259 bp long. In every PCR run two reagent controls,
two positive, and two negative samples were included. All samples
were run in duplicate from the beginning of the extraction procedure
until gel analysis and congruent result only were accepted.
Results
HBJ/-infection
HBV serology. None of our 67 patients undergoing chronic
hemodialysis was HBsAg+. 17 patients had signs of past HBV
Table 2. Characteristics of patients with HBV-DNA or HCV-RNA in
PMNC
Viral genome in PMNC Serological status PCR in serum
Patients with HBV-DNA
in PMNC
N = 5 (7.5%)
3 HBsAg— anti-HBs+
anti-HBc--
HBV-DNA--
2 HBsAg- antiHBs-
anti-HBc—
HBV-DNA-
0 HBsAg— anti-HBs+
anti-HBc+
HBV-DNA---
0 FIBsAg- antiHBs—
anti-HBc+
HBV-DNA-
Patients without HBV-DNA
in PMNC
N = 62 (92.5%)
29 HBsAg— anti-HBs+
anti-HBc---
HBV-DNA—
16 HBsAg— anti-HBs--
anti-HBc—
HBV-DNA-
15 HBsAg— anti-HBs+
anti-HBc +
HBV-DNA—
2 HBsAg- anti-HBs-
anti-HBc+
HBV-DNA
Patients with HCV-RNA
in PMNC
N = 6 (8.9%)
3 Anti-HCV+ HCV-RNA+
2 Anti-HCV- HCV-RNA+
0 Anti-HCV+ HCV-RNA-
1 Anti-HCV- HCV-RNA-
Patients without HCV-RNA
in PMNC
N = 61(91.1%)
4 Anti-HCV+ HCV-RNA+
1 Anti-HCV- HCV-RNA+
3 Anti-HCV+ HCV-RNA-
53 Anti-HCV--- HCV-RNA--
infection (anti-HBc+), 15 of them were anti-HBs+, two were
anti-HBs---. All 52 anti-HBs— patients had been included in a
vaccination program: 32 of the vaccinated patients were classsified
as responders, whereas 20 were non-responders to vaccination.
HBV-DNA in serum. In none of the patients could HBV-DNA
be detected in serum by PCR.
1-lB V-DNA in PMNC. In 5 out of 67 patients (5.7%) HBV-DNA
was detected in PMNC (Table 2). Interestingly, HBV in PMNC
was found in 3 of 32 anti-HBs+ anti-HBc— responders to
vaccination and in 2 of 18 anti-HBs— and anti-HBc--- non-
responders to vaccination, but in none of the 17 patients with
markers of past HBV infection (anti-HBc+). HBV-DNA was
present in PMNC of 13 out of 16 patients with chronic hepatitis B,
but was not detectable in PMNC of 21 healthy controls.
HCV-infection
HCV-serology. Ten (15%) of the 67 patients undergoing chronic
hemodialysis were positive for anti-HCV.
HCV-RNA in serum. Only 7 of the 10 anti-HCV+ patients had
HCV-RNA in serum. However, in 3 (5.3%) of the remaining 57
anti-HCV-- patients HCV-RNA was found to be present in
serum.
1970 Oesterreicher et al: HBV and HCJ/ in PMNC of HD patients
HCV-RNA in PMNC. We found HCV-RNA in PMNC in 6
(8.9%) of 67 patients (Table 2). Three of them were also
anti-HCV+ and serum HCV-RNA+, 2 were anti-HCV— but
serum HCV-RNA+, whereas 1 patient was both anti-HCV— and
serum HCV-RNA--. HCV-RNA could be detected in PMNC of
all 15 patients with chronic hepatitis C, but not in PMNC of 21
healthy controls.
Double infection with HB1 and 1-ICV. One of our patients had
evidence for infection with both HBV and HCV. HBV-DNA was
found in PMNC and HCV-RNA in serum, but neither serological
markers for HBV (HB5Ag—, anti-HBc—, serum HBV-DNA—)
nor HCV (anti-HCV—) infection were present.
Clinical correlations
We compared clinical features of patients (N = 15 (22%)) with
the presence of viral genomes (HBV-DNA or HCV-RNA in
serum and/or PMNC) with those of patients (N — 52; 78%)
without evidence for the presence of hepatitis viral genomes
(negative for HBV-DNA and HCV-RNA in serum and PMNC).
Only 13% of the infected patients undergoing hemodialysis had
elevated aminotransferases; the mean values were within the
normal range (AST (13 12 U/liter), ALT (14 9 U/liter).
Patients with evidence for the presence of hepatitis viral genomes
had significantly higher serum levels of markers for cholestasis,
such as alkaline phosphatase and YGT, and lower levels of
pseudocholinesterase than patients without evidence for the pres-
ence of hepatitis viral genomes (Table 1). No other laboratory
differences were found between these two groups. Neither mean
duration of hemodialysis (58 54 months vs. 41 30months) nor
number of blood units transfused (6 4 vs. 5 6) was different
in these groups. No difference in laboratory and clinical parame-
ters was found in patients with infection of PMNC only as
compared to patients with viral infection detected in serum.
Discussion
In the present paper we describe the prevalence of HBV and
HCV genomes in PMNC of patients undergoing chronic hemo-
dialysis and present evidence that in 8.9% of patients infection
with those viruses is detectable in PMNC only, without concom-
itant presence of viremia, antigenemia or specific antibodies in
serum. Thus, testing of PMNC for infection with hepatitis virus B
and C is useful in the positive identification of potentially infec-
tious patients.
HBV [61 and HCV [7, 8, 10] are able to infect PMNC, as shown
in both patients with [6, 10] and without [15, 16] liver disease as
evidenced by elevated serum aminotransferases. HBV and HCV
genomes are transcribed [7, 17] and replicate [17] in PMNC, and
are thought to constitute an important viral reservoir which
possibly accounts for recurrence of hepatitis virus infection in
certain clinical situations such as liver transplantation [9, 18].
HBV and HCV viral sequences have been found in a high
percentage in PMNC in patients with circulating serum HBV-
DNA [191 and HCV-RNA [16], respectively. In addition, both the
HBV virus genome [15] and HCV-RNA [10] have also been
demonstrated in PMNC in the absence of detectable hepatitis
virus genonies in serum. Similarly, in hepatitis B infection the
presence of HBV-DNA in tissues other than PMNC, such as liver,
in the absence of HBV-DNA in serum has not only be demon-
strated using sensitive PCR techniques [20], but also by relatively
insensitive hybridization assays [6]. These findings are in accor-
dance with results obtained in the patients investigated in this
study: we found HBV-DNA in PMNC in five patients and
HCV-RNA in PMNC in one patient without concomitant pres-
ence of viral genomes in serum. Thus, testing for HBV-DNA or
HCV-RNA in PMNC in addition to serum is a more sensitive
approach than serum testing alone.
Furthermore, HBV-DNA and HCV-RNA have been detected
in PMNC in patients without any serologic markers of HBV [15,
211 or HCV infection [10]. This was also seen in our patients
undergoing chronic hemodialysis as HBV-DNA was found in
PMNC of 2 of 67 (2.9%) patients without any serologic markers
for HBV infection. Similarly, in 5.3% of patients without anti-
HCV PMNC were positive for HCV-RNA. Our findings are
further illustration of the well known fact that hepatitis viral
genomes can be present in the absence of serological markers of
infection.
In addition, HBV-DNA can be found in serum even in the
absence of any serologic markers of HBV infection [21]. This was
not the case in our patients. However, in hepatitis C the detection
of HCV-RNA in sera of anti-HCV negative patients has fre-
quently been reported in hemodialysis patients [2, 22]; this was the
case in one of our patients. An impaired immune response in
patients with uremia [23] might be the reason for the absence of
specific antibodies.
In three anti-HBc negative patients HBV-DNA was found in
PMNC despite the presence of anti-HBs which were the result of
previous HBV vaccinations; it is tempting to speculate that
PMNC are a site of long-lasting latent HBV infection which might
persist even beyond the time of gradual loss of naturally acquired
anti-HBs and anti-HBc. The anti-HBs in these patients might be
an anamnestic immune response to vaccination given to individ-
uals with unrecognized persistent infection.
False positive results are always of concern when using PCR
techniques. We think, however, that strict adherence to precau-
tions as outlined by Kwok and Higuchi [11], the use of a closed
system for blood drawing (vacutainer), and the addition of
negative controls in every PCR run makes false-positive reactions
due to contaminations unlikely. Furthermore, HBV-DNA and
HCV-RNA in PMNC do not seem to be a carryover of virus
particles from serum as: (i) positive results were seen in patients
with PCR-negative serum; (ii) the last washing fluid of PMNC was
always PCR negative; and (iii) and actual transcription of HBV-
DNA [17] or HCV-RNA [7, 10, 16] as opposed to positivity due to
mere adherence of virus particles to the cell membrane of PMNC
has been convincingly demonstrated.
Most of our patients with evidence of HBV or HCV infection
had normal serum aminotransferase levels. Only 2 out of 15
infected patients had ALT levels above normal. Although patients
with evidence for presence of viral genomes had higher serum
levels of ALT as compared to those without evidence for viral
infection, the absolute ALT values were well within normal range.
Patients with evidence for hepatitis viral infection had increased
markers of cholestasis (yGT, alkaline phosphatase), as described
for this patient group [24]. No difference could be found in
laboratory parameters in patients with infection of PMNC only,
compared to patients with hepatitis virus present in serum. These
data are in agreement with reports for HBV [25] and HCV [22]
infection in hemodialysis patients in which ALT levels had no
predictive value for hepatitis virus infection due to the frequent
finding of normal ALT values.
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Patients undergoing chronic hemodialysis are at an increased
risk to acquire HBV and HCV infection [1]. Several factors such
as duration of hemodialysis [4], number of blood units transfused
[51, and non-separation of infected from non-infected patients
[26] have been associated with infection. However, even in dialysis
units with low prevalence of HBV and HCV infection and strict
adherence to guidelines for avoiding transmission of blood-borne
infectious agents [27], the infection rate with hepatitis viruses is
still higher than in the general population [28]. Patients with
hepatitis virus genomes in PMNC but without serologic evidence
of infection or viral genomes in serum might constitute a hidden
source of infection and contribute to "sporadic" infection in
dialysis units [29]. Similarly, after renal transplantation patients
are still at risk to acquire hepatitis virus infection [30] even
without a continuing need for hemodialysis or blood transfusion.
Unrecognized chronic infection with HBV or HCV, possibly
reactivated by immunosuppression after transplantation, might be
the cause for reappearance of serologically documented infections
in these patients; by searching for HBV and HCV in PMNC occult
infections with these viruses might be uncovered.
In conclusion, a small, but significant proportion of hemodial-
ysis patients have evidence for infection with HBV and HCV in
PMNC despite the absence of viral genomes, viral antigens, or
specific viral antibodies in serum. Thus, surveillance performed by
serology and PCR from serum may underestimate the true rate of
infection with hepatitis viruses. These data underscore the need
for adequate and continuing prophylactic measures, even in a
population of hemodialysis patients who are negative for serologic
viral markers or serum hepatitis genomes, to limit the spread of
hepatitis virus infection within dialysis units.
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